Qualification and Validation
Sets out the principles of qualification and validation applicable to facilities, equipment, utilities, and processes used in the manufacture of medicinal products. Introduces the lifecycle approach and continued process verification concept.
What this does not cover
stated in the document's own scope- Covers qualification and validation of facilities, equipment, utilities and processes; the sterile-product controls themselves are set in Annex 1.
- Sets validation of computerised systems at a high level, with the detailed expectations carried by Annex 11.
- Addresses validation methodology, not the routine production controls, which are the subject of the main GMP chapters.
- Applies to manufacture, not to the distribution of validated product, which falls under the EU GDP guidelines.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
EU GMP Annex 15, "Qualification and Validation", is the guidance that sets out how facilities, equipment, utilities and processes used to make medicinal products are qualified and validated. It describes the validation master plan and the qualification stages — design, installation, operational and performance qualification — then covers process validation, cleaning validation, validation of analytical methods and computerised systems, and the control of change and deviation. The 2015 revision moved the annex onto a lifecycle footing: process validation is treated as an ongoing activity supported by continued process verification rather than a one-off exercise completed at launch.
Scope & applicability
All EU GMP-regulated manufacturers. Applies to new and existing facilities, equipment, utilities, and manufacturing processes.
Legal basis & how it acquires force
Annex 15 is part of Volume 4 of EudraLex, the EU GMP Guide, and elaborates the qualification and validation obligations that flow from the EU GMP Directives and the main guide (notably Chapter 5, Production). It is guidance, but conformance is expected of every holder of a manufacturing authorisation. The revised version was published in March 2015 and came into operation on 1 October 2015, updating the annex to reflect ICH Q8–Q11 concepts and the shift in regulatory thinking toward science- and risk-based lifecycle validation.
Document structure
| Part | Covers |
|---|---|
| Organising validation | The validation master plan, documentation, and the qualification/validation lifecycle |
| Qualification stages | Design, installation, operational and performance qualification (DQ/IQ/OQ/PQ) |
| Process validation | Traditional, continuous and hybrid approaches, plus ongoing/continued process verification |
| Transport and packaging verification | Verification of transportation and of packaging processes |
| Utilities and cleaning validation | Qualification of utilities and validation of cleaning, including limit justification |
| Change and revalidation control | Change control and the triggers for requalification and revalidation |
Key requirements
- Validation Master Plan (VMP) — site-level document describing validation approach and philosophy
- Risk-based qualification using a documented risk assessment to determine IQ/OQ/PQ scope
- Process validation lifecycle: design qualification, process qualification, continued verification
- Cleaning validation with scientifically justified limits and worst-case selection rationale
- Transport validation for products with defined storage requirements
- Change control — all changes assessed for requalification/revalidation requirements
Implementation tips
- VMP should be updated annually or when significant changes occur — treat it as a living document
- Document the scientific basis for worst-case equipment and product selection in cleaning validation
- Qualification protocols must be approved before execution — retroactive approval is not acceptable
Revision notes
Current version October 2015. Introduced lifecycle approach replacing older three-batch paradigm. No changes since 2015.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Annex 15 aligns with the ICH quality guidelines — Q8 (pharmaceutical development), Q9 (quality risk management), Q10 (pharmaceutical quality system) and Q11 (development and manufacture of drug substances) — which is why its 2015 revision adopted a lifecycle model. Its process-validation stages correspond conceptually to the FDA’s three-stage process-validation lifecycle, and it works alongside Annex 1 for sterile processes and Annex 11 for computerised systems.
EU GMP Annex 15: frequently asked questions
Quick answers to common questions about EU GMP Annex 15.
When did the current EU GMP Annex 15 take effect?
The revised Annex 15 was published in March 2015 and came into operation on 1 October 2015, replacing the earlier 2001 version and moving qualification and validation onto a lifecycle basis.
What qualification stages does Annex 15 describe?
Annex 15 sets out design qualification, installation qualification, operational qualification and performance qualification (DQ, IQ, OQ, PQ), together with process validation and continued process verification across the product lifecycle.
What is continued process verification in Annex 15?
It is the ongoing collection and evaluation of process data during routine commercial production to confirm the process remains in a state of control — the lifecycle element the 2015 revision introduced so that validation is treated as continuous rather than completed once at launch.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.